EMA Authorised: Lynozyfic (linvoseltamab) — Regeneron Ireland Designated Activity Company (DAC)

View source ↗

Summary

EMA authorised Lynozyfic (linvoseltamab) for multiple myeloma with conditional approval; Regeneron Ireland DAC is the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• LYNOZYFIC (LINVOSELTAMAB-GCPT)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Regeneron Ireland Designated Activity Company (DAC). Decision date: 21/07/2025. Conditional approval